share_log

Cantor Fitzgerald Reiterates Overweight on Tourmaline Bio, Maintains $25 Price Target

Cantor Fitzgerald Reiterates Overweight on Tourmaline Bio, Maintains $25 Price Target

Cantor Fitzgerald重申对Tourmaline Bio的增持评级,维持25美元的目标价
Benzinga ·  12/11 17:24  · 评级/大行评级

Cantor Fitzgerald analyst Josh Schimmer reiterates Tourmaline Bio (NASDAQ:TRML) with a Overweight and maintains $25 price target.

坎托·菲茨杰拉德的分析师乔什·希默重申对Tourmaline Bio(纳斯达克:TRML)的增持评级,并维持25美元的价格目标。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发